Projects and Grants per year
Personal profile
Education/Academic qualification
Post Doctoral Fellow, Stanford University
2019
Post Doctoral Fellow, New York Medical College
2018
Residency, New York Medical College
2015
Bachelor of Medicine, Bachelor of Surgery, Stanley Medical College
2011
-
24-NHL-40-AB (M22-128): A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Iragavarapu, C. (PI)
1/15/25 → 1/15/27
Project: Research project
-
24-NHL-39-FTI-PMC(FT522-101): A Phase 1 Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma
Iragavarapu, C. (PI)
Fate Therapeutics Incorporated
10/28/24 → 10/28/26
Project: Research project
-
24-NHL-38-AT-PMC (ALLO-501A-202): A Randomized, Open-Label Study Evaluating The Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA 3)
Iragavarapu, C. (PI)
Allogene Therapeutics Incorporated
8/9/24 → 8/9/26
Project: Research project
-
24-NHL-37-RG (R1979-ONC-2105): A Phase 3, Open Label, Randomized Study Comparing The Efficacy and Safety of Odronextamab (Regn1979), An Anti-Cd20 ? Anti-Cd3 Bispecific Antibody, in Combination With Chop (O-Chop) Versus Rituximab in Combination With Chop (
Iragavarapu, C. (PI)
6/14/24 → 6/14/26
Project: Research project
-
23-NHL-33-RG (R1979-ONC-2075): A Phase 3, Open-Label, Randomized Study to Compare the Safety and Efficacy of Odronextamab (REGN1979), An Anti-CD20 X Anti-CD3 Bispecific Antibody, Combined with Chemotherapy Versus Rituximab Combined with Chemotherapy In Pr
Iragavarapu, C. (PI)
1/30/24 → 1/30/26
Project: Research project